Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among US adults

被引:97
作者
Hyre, Amanda D.
Muntner, Paul
Menke, Andy
Raggi, Paolo
He, Jiang
机构
[1] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
[3] Emory Univ, Sch Med, Dept Med Radiol, Atlanta, GA USA
关键词
lipoproteins; LDL cholesterol; guidelines; NHANES;
D O I
10.1016/j.annepidem.2007.01.032
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: We sought to determine trends in the prevalence, awareness, treatment and control of high low-density lipoprotein (LDL) cholesterol among U.S. adults. METHODS: Data from 6497 participants of the Third National Health and Nutrition Examination Survey (NHANES) conducted in 1988-1994 and 5626 participants of NHANES 1999-2004 were compared. High LDL cholesterol was defined using risk-specific cut-points from the National Cholesterol Education Program's Adult Treatment Panel III guidelines. RESULTS: The age -standardized percentage of U.S. adults with high LDL cholesterol was 26.6% in 1988-1994 and 25.3% in 1999-2004 (P = 0.28). Between 1988-1994 and 1999-2004, awareness increased from 39.2% to 63.0%, and use of pharmacologic lipid-lowering treatment increased from 11.7% to 40.8% (each p < 0.001). LDL cholesterol control increased from 4.0% to 25.1% among those with high LDL cholesterol (p < 0.001). In 1999-2004, rates of LDL cholesterol control were lower among adults ages 20-49 years compared with those age 65 years or older (13.9% vs. 30.3%; p < 0.001); non-Hispanic blacks and Mexican-Americans compared with non-Hispanic whites (17.2% and 16.5% vs. 26.9%, respectively; p = 0.05 and p = 0.008); and males compared with females (22.6% vs. 28.0%; p = 0.01). CONCLUSIONS: Continued efforts are needed to lower the burden of high LDL cholesterol and increase LDL cholesterol control, especially among populations with low control rates.
引用
收藏
页码:548 / 555
页数:8
相关论文
共 20 条
  • [1] [Anonymous], 2002, JAMA
  • [2] Discovering the full spectrum of cardiovascular disease - Minority health summit 2003 - Report of the outcomes writing group
    Benjamin, EJ
    Jessup, M
    Flack, JM
    Krumholz, HM
    Liu, K
    Nadkarni, VM
    Rhoades, DA
    Rodriguez, BL
    Scott, RP
    Taylor, MP
    Velazquez, EJ
    Winkleby, MA
    [J]. CIRCULATION, 2005, 111 (10) : E124 - E133
  • [3] New advances in lipid-modifying therapies for reducing cardiovascular risk
    Bruckert, E
    [J]. CARDIOLOGY, 2002, 97 (02) : 59 - 66
  • [4] Trends in serum lipids and lipoproteins of adults, 1960-2002
    Carroll, MD
    Lacher, DA
    Sorlie, PD
    Cleeman, JI
    Gordon, DJ
    Wolz, M
    Grundy, SM
    Johnson, CL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14): : 1773 - 1781
  • [5] *CDCP, 2001, NAT CANC HLTH STAT N
  • [6] *CDCP, 2002, NAT CANC HLTH STAT N
  • [7] *CDCP, 1992, NAT CANC HLTH STAT N
  • [8] Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P117
  • [9] CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36
  • [10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497